p53 mutations, chronic hepatitis B virus infection, and aflatoxin exposure in hepatocellular carcinoma in Taiwan

Cancer Research

Volumn 57, Issue 16, 1997, Pages 3471-3477

  Lunn, Ruth M ^a   Zhang, Yu Jing ^a   Wang, Li Yu ^b   Chen, Chien Jen ^b   Lee, Po Huang ^c   Lee, Chue Shue ^c   Tsai, Wei Yann ^a   Santella, Regina M ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AFLATOXIN B1; DNA; HEPATITIS B SURFACE ANTIGEN; PROTEIN P53;

ADULT; ARTICLE; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; DNA ADDUCT; EXPOSURE; FEMALE; GENE MUTATION; HEPATITIS B; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

AFLATOXIN B1; CARCINOMA, HEPATOCELLULAR; DNA ADDUCTS; DNA, NEOPLASM; FEMALE; GENES, P53; GENETIC MARKERS; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POINT MUTATION; TUMOR MARKERS, BIOLOGICAL;

EID: 0030791718     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Department of Health, Executive Yuan, and ROC Department of Health. Health Statistics 1993. Taipei: 1993.
2. Yu, M-W., and Chen, C-J. Hepatitis B and C viruses in the development of hepatocellular carcinoma. Crit. Rev. Oncol. Hematol., 17: 71-91, 1994.
3. Hatch, M. C., Chen, C-J., Levin, B., Ji, B-T., Yang, G-Y., Hsu, S-W., Wang, L-W., and Santella, R. M. Urinary aflatoxin levels, hepatitis B virus infection and hepatocellular carcinoma in Taiwan, Int. J. Cancer. 54: 931-934, 1993.
4. Peers, F. G., Bosch, X., Kaldor, J., Linsell, A., and Pluijmen, M. Aflatoxin exposure, hepatitis B virus infection and liver cancer in Swaziland. Int. J. Cancer, 39: 545-553, 1987.
5. Yeh, F. S., Yu, M. C., Mo, C. C., Luo, S., Tong, M. J., and Henderson, B. E. Hepatitis B virus, aflatoxins and hepatocellular carcinoma in southern Guangxi, China. Cancer Res., 49: 2506-2509, 1989.
6. Srivatanakul, P., Parkin, D. M., Jiang, Y-Z., Khlat, M., Kao-Ian, U-T., Sontipong, S., and Wild, C. The role of infection by Opisthorchis viverrini, hepatitis B virus, and aflatoxin exposure in the etiology of liver cancer in Thailand. Carcinogenesis (Lond.), 68: 2411-2417, 1991.
7. Campbell, T. C., Chen, J., Liu, C., Li, J., and Parpia, B. Nonassociation of aflatoxin with primary liver cancer in a cross-sectional ecological survey in the People's Republic of China. Cancer Res., 50: 6882-6893, 1990.
8. Chen, C. J., Wang, L. Y., Lu, S. N., Wu, M. H., You, S. L., Zhang, Y. J., Wang, L. W., and Santella, R. M. Elevated aflatoxin exposure and increased risk of hepatocellular carcinoma. Hepatology, 24: 38-42, 1996.
9. Chen, C. J., Yu, M. W., Liaw, Y. F., Wang, L. W., Chiamprasert, S., Matin, F., Hirvonen, A., Bell, D. A., and Santella, R. M. Chronic hepatitis B carriers with null genotypes of glutathione S-transferase M1 and T1 polymorphisms who are exposed to aflatoxin are at increased risk of hepatocellular carcinoma. Am. J. Hum. Genet., 59: 128-134, 1996.
10. Wang, L-Y., Hatch, M. C., Chen, C-J., Levin, B., You, S-L., Lu, S-N., Wu, M-H., Wu, W-P., Wang, L-W., Wang, Q., Huang, G-T., Yang, P-M., Lee, H-S., and Santella, R. Aflatoxin exposure and the risk of hepatocellular carcinoma in Taiwan. Int. J. Cancer, 67: 620-625, 1996.
11. Ross, R. K., Yuan, J. M., Yu, M. C., Wogan, G. N., Qian, G. S., Tu, J. T., Groopman, J. D., Gao, Y. T., and Henderson, B. E. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet, 139: 943-946, 1992.
12. Qian, G. S., Ross, R. K., Yu, M. C., Yuan, J. M., Gao, Y. T., Henderson, B. E., Wogan, G. N., and Groopman, J. D. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol., Biomarkers & Prev., 3: 3-10, 1994.
13. McLean, M., and Dutton, M. F. Cellular interactions and metabolism of aflatoxin: an update. Pharmacol. Ther., 65: 163-192, 1995.
14. Greenblatt, M. S., Bennett, W. P., Hollstein, M., and Harris, C. C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res., 54: 4855-4878, 1994.
15. Hsu, I. C., Metcalf, R. A., Sun, T., Welsh, J. A., Wang, N. J., and Harris C. C. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature (Lond.), 350: 427-428, 1991.
16. Bressac, B., Kew, M., Wands, J., and Ozturk, M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature (Lond.), 350: 429-430, 1991.
17. 1 in nonhuman primates. Cancer Res., 52: 1044-1046, 1992.
18. 1-induced rat hepatic hyperplastic nodules do not exhibit a site-specific mutation within the p53 gene. Cancer Res., 53: 9-11, 1993.
19. Rivkina, M. B., Cullen, J. M., Robinson, W. S., and Marion, P. L. State of the p53 gene in hepatocellular carcinomas of ground squirrels and woodchucks with past and ongoing infection with hepadnaviruses. Cancer Res., 54: 5430-5437, 1994.
20. 1 intoxication on duck livers with duck hepatitis B virus infection. Cancer Res., 48: 1559-1564, 1988.
21. Li, D., Cao, Y., He, L., Wang, N. J., and Gu, J. R. Aberrations of p53 gene in human hepatocellular carcinoma from China. Carcinogenesis (Lond.), 14: 169-173, 1993.
22. Sheu, J-C., Huang, G-T., Lee, P-H., Chung, J-C. H., Chou, H-C., Lai, M-Y., Wang, J-T., Lee, H-S., Shih, L-N., Yang, P-M., Wang, T-H., and Chen, D-S. Mutation of p53 gene in hepatocellular carcinoma in Taiwan. Cancer Res., 52: 6098-6100, 1992.
23. Goldblum, J. R., Bartos, R. E., Carr, K. A., and Frank, T. S. Hepatitis B and alterations of the p53 tumor suppressor gene in hepatocellular carcinoma. Am. J. Surg. Pathol., 17: 1244-1251, 1993.
24. Unsal, H., Yakicier, C., Marcais, C., Kew, M., Volkmann, M., Zentgraf, H., Isselbacher, K. J., and Ozturk, M. Genetic heterogeneity of hepatocellular carcinoma. Proc. Natl. Acad. Sci. USA, 91: 822-826, 1994.
25. Wang, X. W., Forrester, K., Yeh, H., Feitelson, M. A., Gu, J-R., and Harris, C. C. Hepatitis B virus X protein inhibits p53 sequence-specific CNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc. Natl. Acad. Sci. USA, 91: 2230-2234, 1994.
26. 1-DNA adducts formed in vivo. Cancer Res., 48: 6328-6331, 1988.
27. Shi, S-R., Key, M. E., and Kalra, K. L. Antigen retrieval in formalin-fixed, paraffinembedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J. Histochem. Cytochem., 39: 741-748, 1991.
28. Scopsi, L., and Larsson, L-I. Increased sensitivity in peroxidase immunocytochemistry. A comparative study of a number of peroxidase visualization employing a model system. Histochemistry, 84: 221-230, 1986.
29. Gaidano, G., Ballerine, P., Gong, J. Z., Neri, A., Newcomb, E. W., Magrath, I. T., Knowles, D. M., and Dalla-Favera, R. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemias. Proc. Natl. Acad. Sci. USA, 88: 5413-5417, 1991.
30. Buetow, K. H., Shefield, V. C., Zhu, M., Zhou, T., Shen, F-M., Hino, O., Smith, M., McMahon, B. J., Lanier, A. P., London, W. T., Redeker, A. G., and Govindarajan, S. Low frequency of p53 mutations observed in a diverse collection of primary hepatocellular carcinomas. Proc. Natl. Acad. Sci. USA, 89: 9622-9626, 1992.
31. Murakami, Y., Hayashi, K., Hirohashi, S., and Sekiya, T. Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas. Cancer Res., 51: 5520-5525, 1991.
32. Harrison, J. C., Carvajal, M., and Garner, R. C. Does aflatoxin exposure in the United Kingdom constitute a cancer risk? Environ. Health Perspect., 90: 99-105, 1993.
33. 1-DNA adducts in smeared tumor tissue of hepatocellular carcinoma patients. Hepatology, 16: 1150-1155, 1992.
34. 1-DNA adducts and hepatitis B virus antigens in hepatocellular carcinoma and non-tumorous liver tissue. Carcinogenesis (Lond.), 12: 2247-2252, 1991.
35. Kirby, G. M., Wolf, C. R., Neal, G. E., Judah, D. J., Henderson, C. J., Srivatanakul, P., and Wild, C. P. In vitro metabolism of aflatoxin B, by normal and tumorous liver tissue from Thailand. Carcinogenesis (Lond.), 14: 2613-2620, 1993.
36. Lange, R., Perin, F., Larroque, C., and Zajdela, F. Isolation and partial characterization of a cytochrome P-450 isoenzyme (cytochrome P-450tu) from mouse liver tumors. Biochim. Biophys. Acta, 1038: 130-135, 1990.
37. Jounaidi, Y., Bonfils, C., Perin, F., Negishi, M., and Lange, R. Overexpression of a cytochrome P-450 of the 2a family (Cyp2a-5) in chemically induced hepatomas from female mice. Eur. J. Biochem., 219: 791-798, 1994.
38. 1 binding to DNA in woodchuck hepatocytes. Cancer (Phila.), 73: 596-604, 1994.
39. 1 formamidopyrimidine adducts in human hepatocarcinogenesis: a preliminary report. Gastroenterology, 97: 1281-1287, 1989.
40. Jacobs, T. W., Prioleau, J. E., Stillman, I. E., and Schnitt, S. J. Loss of tumor-marker-immunostaining intensity on stored paraffin slides of breast cancer. J. Natl. Cancer Inst., 88: 1054-1059, 1996.
41. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. p53 mutations in human cancers. Science (Washington DC), 253: 49-53, 1991.
42. Hsieh, D. P., and Atkinson, D. N. Recent aflatoxin exposure and mutation at codon 249 of the human p53 gene: lack of association. Food Addit. Contain., 12: 421-424, 1995.
43. Soni, Y., Chia, S. C., Bennett, W. P., Groopman, J. D., Wang, J. S., DeBenedetti, V. M. G., Cawley, H., Welsh, J. A., Trivers, G. E., Sandoval, C. A., Calderon, I. E., Munoz Espinosa, L. E., and Harris, C. C. An aflatoxin-associated mutational hotspot at codon 249 in the p53 tumor suppressor gene occurs in hepatocellular carcinomas from Mexico. Carcinogenesis (Lond.), 17: 1007-1012, 1996.
44. Robinson, W. S. Molecular events in the pathogenesis of hepadnavirus-associated hepatocellular carcinoma. Annu. Rev. Med., 45: 297-323, 1994.
45. Aguilar, F., Harris, C. C., Sum, T., Hollstein, M., and Cerutti, P. Geographic variation of p53 mutational profile in nonmalignant human liver. Science (Washington DC), 264: 1317-1319, 1994.
46. Teramoto, T., Satonaka, K., Kitazawu, S., Fujimori, T., Hayushi, K., and Maeda, S. p53 gene abnormalities are closely related to hepatoviral infections and occur at a late stage of hepatocarcinogenesis. Cancer Res., 54: 231-235, 1994.
47. Tanaka, S., Toh, Y., Adachi, E., Matsumata, T., Mori, R., and Sugimachi, K. Tumor progression in hepatocellular carcinoma may be mediated by p53 mutation. Cancer Res., 53: 2884-2887, 1993.
48. Hsu, H-C., Tseng, H-J., Lai, P-L., Lee, P-H., and Peng, S-Y. Expression of p53 gene in 184 unifocal hepatocellular carcinomas: association with tumor growth and invasiveness. Cancer Res., 53: 4691-4694, 1993.
49. Konishi, M., Kikuchi-Yanoshita, R., Tanaka, K., Sato, C., Tsuruta, K., Maeda, Y., Koike, M., Tanaka, S., Nakamura, Y., Hattori, N., and Miyaki, M. Genetic changes and histopathological grades in human hepatocellular carcinomas. Jpn. J. Cancer Res., 84: 893-899, 1993.